Trial Profile
Study of dose reduction of abiraterone acetate plus prednisone or enzalutamide and Psa progression in veterans with metastatic castration resistant prostate cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Enzalutamide (Primary) ; Prednisone (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 21 May 2018 Results presented at the 113th Annual Meeting of the American Urological Association
- 21 May 2018 New trial record